Notice of Allowability	Application No.	Applicant(s)
	10/760,493	BACHMANN ET AL.
	Examiner	Art Unit
	Traviss C. McIntosh	1623
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.  1. This communication is responsive to amendment filed 8/30/07.		
2. ⊠ The allowed claim(s) is/are <u>8-13 and 16-33</u> .		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ul>		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5 □ Nation of Informal F	S-AA-A
<ol> <li>Induce of References Cited (PTO-892)</li> <li>Induce of References Cited (PTO-9948)</li> <li>Induce of References Cited (PTO-9948)</li> <li>Induce of References Cited (PTO-9948)</li> </ol>	<ol> <li>5. ☐ Notice of Informal F</li> <li>6. ☑ Interview Summary</li> </ol>	• •
	6. ⊠ Interview Summary Paper No./Mail Da 7. ⊠ Examiner's Amendr	te
<ol> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date</li> </ol>	7. 🔯 Examiner's Amendi	nenvComment
Examiner's Comment Regarding Requirement for Deposit of Biological Material		ent of Reasons for Allowance
	9.	

## **EXAMINER'S AMENDMENT**

## Election/Restrictions

Claims 8-10 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 11-13, directed to the process of making an allowable product, and claims 19-33, directed to the process for using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 1/12/2007 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

Art Unit: 1623

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Drew Hissong on 11/9/2007.

The application has been amended as follows:

In the specification; paragraph [091], bridging pages 44-45 has been deleted and replaced

by the following paragraph:

[091] The deposited cosmids and strains [C03]023 and [C03U03]023 (the deposited

stains) have been made under the terms of the Budapest Treaty on the International Recognition

of the Deposit of Micro-organisms for Purposes of Patent Procedure. The deposited strains will

be irrevocably and without restriction or condition released to the public upon the issuance of a

patent. A license may be required to make, use or sell the deposited strains, and compounds

derived there from, and no such license is hereby granted.

In the claims:

Claim 16 (currently amended): A pharmaceutical composition comprising a

therapeutically effective amount of a compound of claim 10 to treat a fungal infection, and a

pharmaceutically acceptable carrier.

Application/Control Number: 10/760,493

Art Unit: 1623

Claim 17 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 8 to treat a fungal infection, and a pharmaceutically acceptable carrier.

Claim 18 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9 to treat a fungal infection, and a pharmaceutically acceptable carrier.

The following is an examiner's statement of reasons for allowance: the prior art is not seen to teach or fairly suggest the claimed compounds nor the use of the same, moreover, the allowance is predicated on the conditions of the deposit, and in the absence of the deposit the claims would not meet the requirements of 35 USC 112 1<sup>st</sup> paragraph.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Traviss C. McIntosh whose telephone number is 571-272-0657. The examiner can normally be reached on M-F 9:30-6:00.

Application/Control Number: 10/760,493 Page 5

Art Unit: 1623

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Traviss McIntosh November 13, 2007

Shaojia A. Jiang Supervisory Patent Examiner Art Unit 1623